Table 1 Baseline characteristics of patients
Ivabradine group (n = 14) | Placebo group (n = 5) | |
|---|---|---|
Age, years | 61 [59; 67] | 54 [53; 59] |
Male gender, n (%) | 11 (79) | 5 (100) |
BMI, kg/m2 | 27.5 [25.8; 28.9] | 26.2 [25.9; 29.7] |
HR, bpm | 73.5 [65.0; 89.0] | 75.0 [67.0; 77.0] |
SBP, mm Hg | 121 [112; 130] | 115 [114; 125] |
DBP, mm Hg | 71 [66; 73] | 70 [65; 75] |
EuroSCORE | 5.5 [4.5; 6.5] | 4.0 [2.5; 7.5] |
LVEF, n (%) | 31.5 [25.0; 38.0] | 35.0 [27.0; 39.0] |
History of MI, n (%) | 9 (64.0) | 2 (40.0) |
History of PTCA, n (%) | 5 (36.0) | 0 (0.0) |
History of CABG, n (%) | 0 (0) | 0 (0) |
CAD severity, n (%) | ||
1 vessel | 0 (0) | 0 (0.0) |
2 vessels | 1 (7.1) | 0 (0.0) |
3 or more vessels | 13 (92.9) | 5 (100) |
Dyslipidemia, n (%) | 11 (78.6) | 2 (40.0) |
Hypertension, n (%) | 9 (64.3) | 3 (60.0) |
Diabetes, n (%) | 7 (50.0) | 2 (40.0) |
Heart failure, n (%) | 7 (50.0) | 3 (60.0) |
Beta-blocker use, n (%) | 13 (92.9) | 5 (100.0) |
eGFR, mL/min | 82 [67; 110] | 82 [76; 119] |